Tag: Morphic Holding

Analysts have speculated that Eli Lilly’s success with its weight-loss drug Zepbound helped to materialise this noteworthy deal. The firm agreed to pay $57 per Morphic share, which is 79% more than the MORF trading price clocked at market close on Friday 5 July 2024. Bloomberg reported that Dave Ricks, Eli Lilly’s CEO, previously committed…